Shares of Charles River Laboratories International Inc. CRL shed 1.91% to $161.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX ...

The Convention on International Trade in Endangered Species of Wild Fauna and Flora, or CITES, Standing Committee has voted to defer the ...

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

Flagship Harbor Advisors LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) ...

Fifth Third Bancorp cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

In a report released on February 1, Casey Woodring from J.P. Morgan maintained a Hold rating on Charles River Labs (CRL – Research Report), ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

Read here for an analysis of Charles River's (CRL) strong financial performance with high ROE and decreasing liabilities, indicating future capital deployment.

Shares of Charles River Laboratories International Inc. CRL slipped 1.13% to $164.97 Friday, on what proved to be an ...

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call ...

The outlook for Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.